OHR Pharmaceutical, Inc. is a biotechnology company. The company’s products include Squalamine, an anti-angiogenic small molecule with a novel intracellular mechanism that inhibits vascular endothelial, platelet derived and basic fibroblast growth factors to treat the wet form of age-related macular degeneration. It also offers OHR/AVR 118, which is in clinical trial for the treatment of cancer cachexia, a multi-symptom wasting disorder. For more information, visit the company’s website at www.ohrpharmaceutical.net.